Читать книгу Diabetic Retinopathy and Cardiovascular Disease - Группа авторов - Страница 28

1World Health Organisation. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013–2020. Geneva, World Health Organisation, 2013.

2World Health Organisation. Global Health Estimates 2016: Deaths by Cause, Age, Sex, by Country and by Region, 2000–2016. Geneva, World Health Organisation, 2018.

3United Nations General Assembly. Resolution 70/1. Transforming Our World: the 2030 Agenda for Sustainable Development. New York, United Nations, 2015.

4Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–2222.

5Cho NH, Shaw JE, Karuranga S, et al: IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract 2018;138:271–281.

6Holman N, Young B, Gadsby R: Current prevalence of type 1 and type 2 diabetes in adults and children in the UK. Diabet Med 2015;32:1119–1120.

7NCD Risk Factor Collaboration (NCD-RisC): Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet 2016;387:1513–1530.

8Zimmet PZ, Magliano DJ, Herman WH, Shaw JE: Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol 2014;2:56–64.

9Gluckman PD, Hanson MA, Cooper C, Thornburg KL: Effect of in utero and early-life conditions on adult health and disease. N Engl J Med 2008;359:61–73.

10Low Wang CC, Hess CN, Hiatt WR, Goldfine AB: Clinical update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus – mechanisms, management, and clinical considerations. Circulation 2016;133:2459–502.

11Marwick TH, Ritchie R, Shaw JE, Kaye D: Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy. J Am Coll Cardiol 2018;71:339–351.

12Shah AD, Langenberg C, Rapsomaniki E, et al: Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105–113.

13Chatterjee S, Khunti K, Davies MJ: Type 2 diabetes. Lancet 2017;389:2239–2251.

14Roth GA, Huffman MD, Moran AE, et al: Global and regional patterns in cardiovascular mortality from 1990 to 2013. Circulation 2015;132:1667–1678.

15Harding JL, Shaw JE, Peeters A, Guiver T, Davidson S, Magliano DJ: Mortality trends among people with type 1 and type 2 diabetes in Australia: 1997–2010. Diabetes Care 2014;37:2579–2586.

16Gregg EW, Li Y, Wang J, et al: Changes in diabetes-related complications in the United States, 1990–2010. N Engl J Med 2014;370:1514–1523.

17Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–1197.

18Colagiuri S, Lee CM, Wong TY, et al: Glycemic thresholds for diabetes-specific retinopathy: implications for diagnostic criteria for diabetes. Diabetes Care 2011;34:145–150.

19Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22:233–240.

20Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405–412.

21Zoungas S, Chalmers J, Ninomiya T, et al: Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012;55:636–643.

22Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229–234.

23Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I: Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009;26:142–148.

24Rana JS, Liu JY, Moffet HH, Jaffe M, Karter AJ: Diabetes and prior coronary heart disease are not necessarily risk equivalent for future coronary heart disease events. J Gen Intern Med 2016;31:387–393.

25Peters SA, Huxley RR, Woodward M: Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia 2014;57:1542–1551.

26Gouni-Berthold I, Berthold HK, Mantzoros CS, Bohm M, Krone W: Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care 2008;31:1389–1391.

27Ryden L, Grant PJ, Anker SD, et al: ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013;34:3035–3087.

28American Diabetes Association: 9. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. Diabetes Care 2018;41(suppl 1):S86–S104.

29National Institute for Health and Care Excellence (NICE). Clinical Guideline 181: Cardiovascular Disease: Risk Assessment and Reduction, Including Lipid Modification. London, NICE, 2014.

30Kannel WB, McGee D, Gordon T: A general cardiovascular risk profile: the Framingham Study. Am J Cardiol 1976;38:46–51.

31van Dieren S, Beulens JW, Kengne AP, et al: Prediction models for the risk of cardiovascular disease in patients with type 2 diabetes: a systematic review. Heart 2012;98:360–369.

32Woodward M, Tunstall-Pedoe H, Peters SA: Graphics and statistics for cardiology: clinical prediction rules. Heart 2017;103:538–545.

33Hajifathalian K, Ueda P, Lu Y, et al: A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol 2015;3:339–355.

34Karmali KN, Persell SD, Perel P, Lloyd-Jones DM, Berendsen MA, Huffman MD: Risk scoring for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;3:CD006887.

35Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ: Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ 2000;320:686–690.

36Hall LM, Jung RT, Leese GP: Controlled trial of effect of documented cardiovascular risk scores on prescribing. BMJ 2003;326:251–252.

37International Diabetes Federation Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. Brussels, International Diabetes Federation, 2012.

38British Cardiac Society; British Hypertension Society; Diabetes UK; HEART UK; Primary Care Cardiovascular Society; Stroke Association: JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(suppl 5):v1–v52.

39World Health Organisation. Prevention of Cardiovascular Disease: Guidelines for Assessment and Management of Cardiovascular Risk. Geneva, World Health Organisation, 2007.

40National Vascular Disease Prevention Alliance. Guidelines for the Management of Absolute Cardiovascular Disease Risk. Canberra, National Vascular Disease Prevention Alliance, 2012.

41Backholer K, Hirakawa Y, Tonkin A, et al: Development of an Australian cardiovascular disease mortality risk score using multiple imputation and recalibration from national statistics. BMC Cardiovasc Disord 2017;17:17.

42Hippisley-Cox J, Coupland C, Brindle P: Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.

43Bachmann KN, Wang TJ: Biomarkers of cardiovascular disease: contributions to risk prediction in individuals with diabetes. Diabetologia 2018;61:987–995.

44Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O: Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156–163.

45Hendriks SH, van Dijk PR, van Hateren KJ, et al: High-sensitive troponin T is associated with all-cause and cardiovascular mortality in stable outpatients with type 2 diabetes (ZODIAC-37). Am Heart J 2016;174:43–50.

46Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T: High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care 2006;29:329–333.

47Scirica BM, Bhatt DL, Braunwald E, et al: Prognostic implications of biomarker assessments in patients with type 2 diabetes at high cardiovascular risk: a secondary analysis of a randomized clinical trial. JAMA Cardiol 2016;1:989–998.

48Looker HC, Colombo M, Agakov F, et al: Protein biomarkers for the prediction of cardiovascular disease in type 2 diabetes. Diabetologia 2015;58:1363–1371.

49Gerstein HC, Pare G, McQueen MJ, et al: Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia. Circulation 2015;132:2297–2304.

50van der Leeuw J, Beulens JW, van Dieren S, et al: Novel biomarkers to improve the prediction of cardiovascular event risk in type 2 diabetes mellitus. J Am Heart Assoc 2016;5:pii:e003048.

51Knowles JW, Ashley EA: Cardiovascular disease: the rise of the genetic risk score. PLoS Med 2018;15:e1002546.

52Cox AJ, Hsu FC, Ng MC, et al: Genetic risk score associations with cardiovascular disease and mortality in the Diabetes Heart Study. Diabetes Care 2014;37:1157–1164.

53Goldstein BA, Navar AM, Carter RE. Moving beyond regression techniques in cardiovascular risk prediction: applying machine learning to address analytic challenges. Eur Heart J 2017;38:1805–1814.

54Jonnagaddala J, Liaw ST, Ray P, et al: Identification and progression of heart disease risk factors in diabetic patients from longitudinal electronic health records. BioMed Res Int 2015;e636371.

Prof. Jonathan Shaw

Clinical and Population Health

Baker Heart and Diabetes Institute, PO Box 6492

Melbourne, VIC 3004 (Australia)

E-Mail Jonathan.Shaw@baker.edu.au